AVII Financial Facts
Acquired in-process research and development: 0Revenues from license fees, grants and research contracts: 7.52M
See Full Income Statement
Other liabilities: 105K
Deferred revenue: 3.3M
See Full Balance Sheet
AVI Biopharma, Inc. (AVII) Earnings
|
Expand Research on AVII
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +40.5% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -1.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/10/12  |
Q112 | -$0.13 | -$0.07 | -$0.06 | $11.2M | $11.05M | N/A |  | | Details | |
| 3/1/12 |
 |
Q411 | -$0.01 | -$0.06 | +$0.05 | $13.6M | $11.03M | N/A | | | Details |
| 11/3/11 |
|
Q311 | -$0.03 | -$0.06 | +$0.03 | N/A | $13.88M | = | | | Details |
| 8/4/11 | Q211 | $0.01 | -$0.07 | +$0.08 | $11.6M | $13.67M | = | | | Details | |
| 5/5/11 |
|
Q111 | $0.02 | -$0.03 | +$0.05 | $15.3M | $13.55M | = | | | Details |
| 3/10/11 |
|
Q410 | -$0.07 | -$0.07 | $0.00 | $15.5M | $11.65M | = | | | Details |
